

Erratum Corrige

Dr Rof Rau, the author of “**Efficacy of methotrexate in comparison to biologics in rheumatoid arthritis**” published in Supplement 61: **Methotrexate in Rheumatic Diseases** (*Clin Exp Rheumatol* 2010; 28 (Suppl. 61): S58-S64). has pointed out that there is a mistake in the data in Table III on page S-64 refering to the results of Tocilizumab.

Here below, Table III is reproduced with the correct datum, and the corrections in the paragraph containing the same results on page S-63. All corrections are in **bold**

Tocilizumab

About 93% of patients in both groups completed the 24 weeks of the study. The ACR response rates were significantly smaller with MTX than with tocilizumab treatment. At 24 weeks, the ACR20 response rate of MTX *versus* tocilizumab was 52.5% *vs.* 69.9%, the ACR50 response rate was **33.5% *vs.* 44.1%**, respectively. A DAS28 remission was achieved in 12.1% and **33.6%**, respectively.

Table III. Clinical and radiographic results in trials comparing MTX with biologics head to head.

ACR response of MTX <i>vs.</i> biologic							Radiologic progression with MTX <i>vs.</i> biologic			
Biologic	endpoint	ACR 20%	ACR 50%	signif.	DAS remission	ref.	endpoint	Sharp units	sign	no score-increase
Etanercept ERA	12 mo	65/72	~45/~50 *	no	--	1, 2	6 mo	1.06/0.57	yes	--
							12 mo	1.59/1.06	no	--
							24 mo	3.2 /1.3	yes	51/63%
Etanercept TEMPO	12 mo	75/76	43 /48	no	13/16	4	12 mo	2.8/ 0.52	yes	
	36 mo	70/71	44 /46	no		6	36 mo	5.95/1.61	yes	51/61%
Adalimumab PREMIER							6 mo	3.5 /2.1		
	12 mo	63 /54	46 /41	no		8	12 mo	5.7 /3.0	yes	
	24 mo	56 /48	43 /37	no	25/25		24 mo	10.4/5.5	yes	34/45%
Golimumab	6 mo	~52 /54	29 /33	no	28/25	9	6 mo	--		--
Tocilizumab	6 mo	53 /70	33 /45	yes	12/34	13	6 mo	--		